This strategy is being pursued in an ongoing phase III trial for newly-diagnosed high-risk neuroblastoma patients with amplification or mutation of ALK who will receive crizotinib in combination with all planned adjuvant therapy (ClinicalTrials.gov Identifier: NCT03126916, Table 2). This evidence concerns the gene ALK and neuroblastoma.